- Home
- AGCC vs PROF Comparison
AGCC vs PROF Comparison
Compare AGCC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGCC | PROF |
|---|---|---|
| Founded | 2020 | N/A |
| Country | Taiwan | Canada |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 230.4M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGCC | PROF |
|---|---|---|
| Price | $9.05 | $7.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 151.4K | ★ 232.3K |
| Earning Date | 02-23-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $3,038,946.00 | ★ $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | $161.04 | ★ N/A |
| Revenue Growth | ★ 186.00 | 67.94 |
| 52 Week Low | $3.66 | $3.76 |
| 52 Week High | $14.72 | $8.95 |
Technical Indicators
Market Signals| Indicator | AGCC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.13 |
| Support Level | N/A | $7.59 |
| Resistance Level | N/A | $8.60 |
| Average True Range (ATR) | 0.00 | 0.59 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 26.15 |
Price Performance
Historical ComparisonAbout AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares
Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.